Antibody-drug conjugates (ADCs) and immunotherapy have prompted a revolution in the treatment of cancer. However, only a limited fraction of patients obtained a long-term benefit; consequently, combination studies have become a central focus of the current preclinical and clinical research in oncology. A strong biological rationale supports the investigation of combining ADCs with immunotherapy to overcome the occurrence of resistance and improve patient outcomes. ADCs interact with cancer and immune cells by eliciting mechanisms such as immunogenic cell death, antibody-dependent cell-mediated cytotoxicity and dendritic cell activation, ultimately providing potential synergism with immunotherapy. Indeed, ADCs induce tumor-specific adaptive immunity, increasing the infiltration of T cells into the tumor microenvironment, whereas immune-checkpoint inhibitors reinvigorate exhausted T cells, enhancing antitumor immune responses. In light of the promising preclinical data, several clinical trials are currently underway in multiple tumor types to evaluate the safety and activity of combination regimens. Initial evidence from early phase clinical trials has already reported encouraging signals. This review focuses on the combination of ADCs and immunotherapy, highlighting the key mechanisms underlying the synergistic effect and providing an overview of the available clinical evidence in solid tumors. In addition, opportunities to optimize the combination are explored, such as defining the optimal dose, balancing the risks and benefits of dose modifications, and the possibility of developing novel immunoconjugates.

Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives / E. Nicolò, F. Giugliano, L. Ascione, P. Tarantino, C. Corti, S.M. Tolaney, M. Cristofanilli, G. Curigliano. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 106:(2022 May), pp. 102395.1-102395.12. [10.1016/j.ctrv.2022.102395]

Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives

F. Giugliano;L. Ascione;P. Tarantino;C. Corti;G. Curigliano
Ultimo
2022

Abstract

Antibody-drug conjugates (ADCs) and immunotherapy have prompted a revolution in the treatment of cancer. However, only a limited fraction of patients obtained a long-term benefit; consequently, combination studies have become a central focus of the current preclinical and clinical research in oncology. A strong biological rationale supports the investigation of combining ADCs with immunotherapy to overcome the occurrence of resistance and improve patient outcomes. ADCs interact with cancer and immune cells by eliciting mechanisms such as immunogenic cell death, antibody-dependent cell-mediated cytotoxicity and dendritic cell activation, ultimately providing potential synergism with immunotherapy. Indeed, ADCs induce tumor-specific adaptive immunity, increasing the infiltration of T cells into the tumor microenvironment, whereas immune-checkpoint inhibitors reinvigorate exhausted T cells, enhancing antitumor immune responses. In light of the promising preclinical data, several clinical trials are currently underway in multiple tumor types to evaluate the safety and activity of combination regimens. Initial evidence from early phase clinical trials has already reported encouraging signals. This review focuses on the combination of ADCs and immunotherapy, highlighting the key mechanisms underlying the synergistic effect and providing an overview of the available clinical evidence in solid tumors. In addition, opportunities to optimize the combination are explored, such as defining the optimal dose, balancing the risks and benefits of dose modifications, and the possibility of developing novel immunoconjugates.
Antibody-drug conjugates; Immune checkpoint inhibitors; Immunogenic cell death; Immunotherapy; Novel immunoconjugates; Solid tumors
Settore MED/06 - Oncologia Medica
mag-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
dd-1-s2.0-S0305737222000597-main.pdf

accesso riservato

Descrizione: Review
Tipologia: Publisher's version/PDF
Dimensione 1.93 MB
Formato Adobe PDF
1.93 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/985549
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 66
  • ???jsp.display-item.citation.isi??? 59
social impact